- Home
- THAR vs RSLS Comparison
THAR vs RSLS Comparison
Compare THAR & RSLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THAR
- RSLS
- Stock Information
- Founded
- THAR 2017
- RSLS 2002
- Country
- THAR United States
- RSLS United States
- Employees
- THAR N/A
- RSLS N/A
- Industry
- THAR Biotechnology: Pharmaceutical Preparations
- RSLS Medical/Dental Instruments
- Sector
- THAR Health Care
- RSLS Health Care
- Exchange
- THAR Nasdaq
- RSLS Nasdaq
- Market Cap
- THAR 5.5M
- RSLS 4.5M
- IPO Year
- THAR 2022
- RSLS 2007
- Fundamental
- Price
- THAR $1.78
- RSLS $2.39
- Analyst Decision
- THAR Strong Buy
- RSLS Hold
- Analyst Count
- THAR 1
- RSLS 1
- Target Price
- THAR $17.00
- RSLS N/A
- AVG Volume (30 Days)
- THAR 41.3K
- RSLS 4.4M
- Earning Date
- THAR 08-08-2025
- RSLS 08-13-2025
- Dividend Yield
- THAR N/A
- RSLS N/A
- EPS Growth
- THAR N/A
- RSLS N/A
- EPS
- THAR N/A
- RSLS N/A
- Revenue
- THAR N/A
- RSLS $7,175,000.00
- Revenue This Year
- THAR N/A
- RSLS $52.80
- Revenue Next Year
- THAR N/A
- RSLS N/A
- P/E Ratio
- THAR N/A
- RSLS N/A
- Revenue Growth
- THAR N/A
- RSLS N/A
- 52 Week Low
- THAR $0.95
- RSLS $2.23
- 52 Week High
- THAR $6.39
- RSLS $347.86
- Technical
- Relative Strength Index (RSI)
- THAR 57.46
- RSLS 38.10
- Support Level
- THAR $1.60
- RSLS $2.37
- Resistance Level
- THAR $1.88
- RSLS $2.73
- Average True Range (ATR)
- THAR 0.15
- RSLS 0.17
- MACD
- THAR 0.01
- RSLS 0.21
- Stochastic Oscillator
- THAR 71.21
- RSLS 13.33
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
About RSLS ReShape Lifesciences Inc.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus. Geographically, the company operates in the United States, Australia, Europe, and the Rest of world, and the majority of its revenue is generated from the United States.